Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_assertion type Assertion NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_head.
- NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_assertion description "[We suggest that the 20210 G/A prothrombin gene mutation be measured in all women on ERT or before beginning ERT to identify those heterozygous for the thrombophilic prothrombin gene mutation (4%) in whom ERT is contraindicated because of increased risk for ATCVD and thromboembolism, and a second, much larger group of women without the 20210 G/A prothrombin gene mutation (96%) in whom ERT may possibly reduce risk for ATCVD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_provenance.
- NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_assertion evidence source_evidence_literature NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_provenance.
- NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_assertion SIO_000772 11230792 NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_provenance.
- NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_assertion wasDerivedFrom befree-20140225 NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_provenance.
- NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_assertion wasGeneratedBy ECO_0000203 NP928337.RA2mJ_l6sWj5xcnzfvFhraO293ihQzftrQ9MGJhxHBWA0130_provenance.